Ethics and Safety is of the upmost importance to the TAIN
consortium, particularly when developing treatments for very young
children. The WP6 partners are Diurnal Ltd and Charité -
Universitätsmedizin Berlin, who will ensure that the work of the
TAIN consortium meets the highest safety and ethical standards.
The strategic objective of WP6 is to have clear responsibility
for, and to monitor all ethical aspects of, the clinical trials and
to organise short- and long-term monitoring in order to identify
any potential adverse drug reactions.
TAIN is funded by European Commission FP7 Programme HEALTH